Whatever the case may be, the market does not like the deal as evidence of the sell off from Monday's gain. And as others pointed out, where is the company going to come up with the rest of the money? It is also interesting that Jason wrote not a thing on Lympro. But his over view of ESS and its sordid past is interesting. Would be a huge coup if Amarantus can salvage it and make it into a winner.